trastuzumab deruxtecan

Fri, 28 Oct 2022 15:36:24 -0400

As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Patients with hormone receptor positive (HR+) breast cancer should additionally have received or be ineligible for endocrine therapy.